Skip to main content

Advertisement

SpringerLink
Log in

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer. A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer.

Methods

Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified. Of these, 198 patients with relapsed breast cancer following surgery were included in this study. Rates and patterns of relapse and metastatic spread in HER2+/ER+ and HER2+/ER− patients were analyzed. This analysis was evaluated by the validation patients’ cohort of our institute prospectively.

Results

Median relapse-free survival was longer in the HER2+/ER+ group than in the HER2+/ER− group (32.0 vs. 19.5 months, p = 0.0012). The peak of recurrence occurred at 12 months after surgery in the HER2+/ER− patients. The peak of relapse was later and the level was lower in the HER2+/ER+ patients (66 and 78 months following surgery) than in the HER2+/ER− patients (33 and 39 months following surgery, respectively). This result was reproduced by the validation cohort with great similarity. Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse. Severe bone metastasis (HR 4.48, p = 0.028) and massive hepatic metastasis (HR 5.24, p = 0.043) were identified as independent risk factors for early relapse.

Conclusions

Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  CAS  PubMed  Google Scholar 

  3. Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399–407

    Article  PubMed  Google Scholar 

  4. Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531–542

    Article  CAS  PubMed  Google Scholar 

  5. Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, Aqqarwal A, Sze HG, Bok WS, Yin WC, Tan P (2003) Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12:3245–3258

    Article  CAS  PubMed  Google Scholar 

  6. Munzone E, Curigliano G, Rocca A, Bonizzi G, Goldhirsch A, Nolè F (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:1–4

    Article  Google Scholar 

  7. Loo LW, Grove DI, Williams EM, Neal CL, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541–8549

    Article  CAS  PubMed  Google Scholar 

  8. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66:8266–8273

    Article  CAS  PubMed  Google Scholar 

  9. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261–2267

    Article  CAS  PubMed  Google Scholar 

  10. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549

    Article  CAS  PubMed  Google Scholar 

  11. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P (2006) The tumor suppressor Smad4 is required for transforming growth factor ß-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66:2202–2209

    Article  CAS  PubMed  Google Scholar 

  12. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524

    Article  CAS  PubMed  Google Scholar 

  13. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114

    Article  CAS  PubMed  Google Scholar 

  14. Fogarty MP, Kessler JD, Wechsler-Reya RJ (2005) Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 64:458–475

    Article  CAS  PubMed  Google Scholar 

  15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  CAS  PubMed  Google Scholar 

  16. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005) Molecular evolution of breast cancer. J Pathol 205:248–254

    Article  CAS  PubMed  Google Scholar 

  17. Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163

    Article  CAS  PubMed  Google Scholar 

  18. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739–750

    Article  PubMed  Google Scholar 

  19. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welsch RS, Maqee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643

    CAS  PubMed  Google Scholar 

  20. Park YH, Park MJ, Ji SH, Yi SH, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park KC, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894–900

    Article  CAS  PubMed  Google Scholar 

  21. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616–1622

    Article  CAS  PubMed  Google Scholar 

  22. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666

    Article  CAS  PubMed  Google Scholar 

  23. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fugua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Samsung Biomedical Research Institute grant, #SBRI C-A6-423-3.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, Korea

    Yeon Hee Park, Soohyeon Lee, Jin Seok Ahn & Young-Hyuck Im

  2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Eun Yoon Cho & Yoon La Choi

  3. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Jeong Eon Lee, Seok Jin Nam & Jung-Hyun Yang

Authors
  1. Yeon Hee Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soohyeon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eun Yoon Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoon La Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeong Eon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seok Jin Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jung-Hyun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin Seok Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Young-Hyuck Im
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-Hyuck Im.

Electronic supplementary material

Below is the link to the electronic supplementary material.

(PPT 268 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, Y.H., Lee, S., Cho, E.Y. et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 66, 507–516 (2010). https://doi.org/10.1007/s00280-009-1190-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1190-7

Keywords

Search

Navigation